Novel Compound HY253 Induces Cell Cycle Arrest and Apoptosis in Human Lung Cancer Cells

A novel compound called HY253, derived from the roots of Aralia continentalis, has been found to induce cell cycle arrest at the G1 phase and cytochrome c-mediated apoptosis in human lung cancer A549 cells. According to a recent study from Seoul, Korea, HY253 has shown promising results in inhibiting the growth of lung cancer cells, making it a potential candidate for treating human lung cancer.

Key Takeaways:

• HY253, a novel decahydrofluorene analog, was isolated from the roots of Aralia continentalis and shown to induce cell cycle arrest at the G1 phase in human lung cancer A549 cells.
• Flow cytometric analysis revealed an appreciable G1 phase arrest in A549 cells treated with 35 microM of HY253.
• The effects of HY253 on apoptosis-associated and cell cycle regulatory proteins in A549 cells were examined using Western blot analysis, which revealed an appreciable apoptotic induction in A549 cells treated with 70 microM of HY253 for 48 h.
• HY253-induced apoptosis was associated with cytochrome c release from mitochondria, activation of caspase-9 and -3, and cleavage of poly(ADP-ribose) polymerase (PARP).
• The study suggests that HY253 may be a potent cancer chemotherapeutic candidate for use in treating human lung cancer cells.

Statistics:

• 35 microM of HY253 was used to measure DNA content of A549 cells using flow cytometric analysis.
• 70 microM of HY253 was used to examine apoptotic induction in A549 cells for 24 and 48 h using TUNEL assay.
• 48 h treatment with 70 microM of HY253 resulted in an appreciable apoptotic induction in A549 cells.
• HY253's effects on apoptosis-associated and cell cycle regulatory proteins in A549 cells were examined using Western blot analysis.

Sources:

• H.L. Oh et al., Journal of Ethnopharmacology, 2010;129(1):135-9.
• Cancer Weekly, Copyright 2010, Cancer Weekly via NewsRx.com.